Business Wire

Axonics® Submits Pivotal Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System

Jaa

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of pivotal clinical data from the ARTISAN-SNM pivotal clinical study designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1.

The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal clinical study approved under an FDA Investigational Device Exemption (“IDE”) to evaluate the safety and efficacy of the Axonics r-SNM System for urinary dysfunction. The study was conducted in 14 centers in the U.S. and 5 centers in Western Europe. All patients reached their six-month, post-implant primary endpoint in January 2019.

As the Company announced on February 19, 2019, the clinical study demonstrated that patients implanted with the Axonics r-SNM System received clinically meaningful and statistically significant improvements in Urinary Urgency Incontinence (“UUI”) symptoms and quality of life. Additionally, the study met all primary and secondary endpoints. No serious device-related adverse events have been reported.

The Clinical Study Report (“CSR”) was submitted to the FDA on February 21, 2019 as an amendment to the Company’s premarket approval (“PMA”) application. The CSR provides safety and efficacy results and a detailed analysis of the full cohort of all implanted patients at the six-month post-implant endpoint.

Raymond W. Cohen, CEO of Axonics, commented, “The six-month clinical results from our ARTISAN-SNM pivotal study add to the significant body of evidence that we have submitted and is currently under review at the FDA. Based on ongoing dialogue with the agency, we determined it was advantageous to continue to enrich the current PMA. Our filing strategy is consistent with our primary objective which is to obtain U.S. FDA approval of our r-SNM System in the most efficient and expeditious manner.”

ARTISAN-SNM Top-Line Results

All patients diagnosed with UUI and meeting study criteria were implanted with a tined lead and the Axonics neurostimulator. Efficacy data was collected using a 3-day bladder diary, a validated quality of life questionnaire (ICIQ-OABqol), and a satisfaction questionnaire. Therapy responders were identified as patients with at least 50% reduction in urgency incontinence episodes at follow-up visits as compared to baseline. An as-treated analysis was performed for all 129 implanted patients. At six months, 90% of all implanted patients were therapy responders including 80% of therapy responders with a ≥75% reduction in urgency incontinence episodes of which 34% were completely dry. Across all patients, urgency incontinence episodes per day reduced from 5.6 ± 0.3 (mean ± standard error) at baseline to 1.3 ± 0.2 at six months (p<0.0001). Patients averaged statistically and clinically significant improvement on the composite ICIQ-OABqol score (34 points) at six months as compared to baseline and 93% of all implanted patients were satisfied with their r-SNM therapy.

Premarket Approval (PMA) Status with the U.S. FDA

Axonics filed a PMA application with the FDA in early December 2018 and interim clinical data from the ARTISAN-SNM study the same month. The ARTISAN-SNM CSR was submitted on February 21, 2019. The clinical data disclosed herein has not yet been reviewed by the FDA. Axonics does not anticipate that the filing of the full cohort of six-month clinical data will significantly impact the FDA’s standard 180-day PMA review timeline required to complete its review and issue a decision letter.

Conference Call and Webcast

As previously announced, the Company will host a conference call with the investment community to discuss 2018 fourth quarter and full-year financial results and recent business developments, including clinical data from the ARTISAN-SNM study, on Tuesday, March 5, 2019, at 4:30 p.m. Eastern Time,

Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using passcode 3386378.

A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company's website at ir.axonicsmodulation.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website for 90 days.

About Overactive Bladder and Sacral Neuromodulation

Overactive bladder (OAB) includes urinary urgency incontinence and urinary frequency and affects an estimated 85 million adults in the U.S. and Europe. OAB is caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. SNM therapy is a well-established treatment that has been widely employed to reduce symptoms and restore bladder function and is also employed to treat urinary retention and fecal incontinence. Reimbursement for SNM is well established in the United States and is a covered service in Europe, Canada and Australia.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia and the first SNM system to gain CE mark for full-body MRI conditional labeling. PMA approval for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

1 The Axonics r-SNM System is currently designated as an investigational medical device in the U.S.

Contact information

Axonics’ Contact
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com

Investor & Media Contact
W2Opure
Matt Clawson, +1-949-370-8500
mclawson@w2ogroup.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

AerSale to Build Next Aero Air / Erickson Aero Tanker for Wildfire Suppression26.3.2019 16:00:00 EETTiedote

AerSale ®, a global supplier of mid-life aircraft, engines, used serviceable material, and maintenance, repair, and overhaul (MRO) services, announced today it has signed a contract with Aero Air / Erickson Aero Tanker to build another firefighting air tanker for the company’s fleet at AerSale’s MRO facility in Goodyear, Arizona. Conversion of the 6th MD-87 aircraft, formally begins on April 1 and will mark the sixth such aircraft modification AerSale has completed at Goodyear. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005165/en/ AerSale to Build Next Aero Air / Erickson Aero Tanker for Wildfire Suppression (Photo: Business Wire) “The Erickson Aero Tanker is a very versatile fire bomber and we are proud to continue our work to expand their fleet and add more aerial firefighting power to the skies,” said Charlie McDonald, Senior Vice President MRO Services at AerSale. “This modified aircraft will rank among the bes

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection26.3.2019 15:30:00 EETTiedote

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg; FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available. Biktarvy is the first HIV product that Gilead will launch and commercialize in Japan directly through its local subsidiary, Gilead Sciences K.K. In the United States, Biktarvy has a Boxed Warning in its product label regarding the risk of post-treatment acute exacerbation of hepatitis B. See below for U.S. Important Safety Information as well as the Biktar

Fifth Annual Fortune 500 Employment Brand Report Published by WilsonHCG26.3.2019 15:00:00 EETTiedote

WilsonHCG, a multi-award-winning global talent solutions provider, released its fifth annual Fortune 500 Employment Brand Report. The report analyzes and ranks the employment brand of each of the Fortune 500 companies based on more than 17,000 data points around six key employment branding and promotion categories. It also identifies trends and changes to employee attraction and engagement throughout the hiring process. “Globally, this is the most competitive hiring environment in history,” said John Wilson, CEO of WilsonHCG. “One key finding from the report, many of the high ranked companies are providing candidates with a hyper-personalized experience. A positive and personalized candidate experience is more important than ever before.” Each company within the Fortune 500 was evaluated on the scope of six key employment brand categories grouped into four areas of the hiring process: Awareness & Attraction, Recruitment, Candidate Experience, and Employee Experience. “Executive leaders

Clearpath Brings Velodyne Lidar Technology to Robotics Community as Value-Added Partner26.3.2019 15:00:00 EETTiedote

Velodyne Lidar, Inc. today announced Clearpath Robotics has become a value-add partner to offer its groundbreaking lidar sensors for the Clearpath research robot platform. Clearpath Robotics, headquartered in Canada, offers Velodyne sensors to academic and corporate research organizations on its mobile robots for survey and inspection, oil and gas, agriculture, materials handling and other applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005148/en/ Clearpath’s robotic solutions utilize Velodyne’s state-of-the-art lidar technology, which boasts industry-leading resolution, range, and field of view. (Photo: Business Wire) Clearpath’s robotic solutions utilize Velodyne’s state-of-the-art lidar technology, which boasts industry-leading resolution, range, and field of view. Velodyne sensors create a 360° real-time map of the environment, allowing the robot to detect and avoid obstacles for safe autonomous naviga

ABB Wins Contract to Power the First Chinese-Built Cruise Vessel26.3.2019 14:29:00 EETTiedote

ABB has been awarded a contract to supply an integrated package, including two Azipod® steerable propulsion systems, for the construction of China’s first ever home-grown cruise ship. ABB’s deep domain knowledge in cruise technology coupled with its local expertise makes it the perfect partner to support this significant milestone in the evolution of China’s shipbuilding industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005501/en/ The Azipod® steerable propulsion systems, also used for the construction of China’s first ever home-grown cruise ship, due for delivery in 2023. (Photo: Business Wire) The 323-meter vessel, due for delivery in 2023, can accommodate 5,000 passengers and is designed to suit the tastes of Chinese cruise travelers whose numbers are expected to rise to 8-10 million annually by 2025, according to industry body Cruise Lines International Association (CLIA). “With this project, China is making

Mount Elbert Closes Upsized First Fund at $382 Million26.3.2019 14:00:00 EETTiedote

Mount Elbert Capital Partners (“Mount Elbert”), a real-assets private equity firm with specialized capabilities in internet infrastructure, today announced that it has completed the final closing of its first fund, Mount Elbert Capital Partners Fund 1 (”Fund 1”). The Fund closed on equity commitments totaling $382 million, surpassing the initial target of $290 million. In raising Fund 1, Mount Elbert attracted a range of global investors, including pension funds, endowments, and family offices. Fund 1 was 22% invested at December 31, 2018, investing alongside global institutional investors GIC and OPTrust in EdgeCore Internet Real Estate (“EdgeCore”). EdgeCore is an investment vehicle developing, acquiring, and operating data centers and related infrastructure, and has been initially capitalized with over $900 million of equity targeted to support approximately $2.0 billion in data center development. In addition to Mount Elbert’s investment through Fund 1, Mount Elbert affiliates serv

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme